{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:55:31Z","timestamp":1771329331380,"version":"3.50.1"},"reference-count":67,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T00:00:00Z","timestamp":1631577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/QEQ-MED\/7042\/2014"],"award-info":[{"award-number":["PTDC\/QEQ-MED\/7042\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["FCT\/CPCA\/A2\/6972\/2020"],"award-info":[{"award-number":["FCT\/CPCA\/A2\/6972\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04138\/2020"],"award-info":[{"award-number":["UIDB\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04138\/2020"],"award-info":[{"award-number":["UIDP\/04138\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Estonian Ministry of Education and Research","award":["IUT34-14"],"award-info":[{"award-number":["IUT34-14"]}]},{"name":"European Union European Regional Development Fund through Foundation Archimedes","award":["TK143, Centre of Excellence in Molecular Cell Engineering"],"award-info":[{"award-number":["TK143, Centre of Excellence in Molecular Cell Engineering"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Multiple myeloma is an incurable plasma cell neoplastic disease representing about 10\u201315% of all haematological malignancies diagnosed in developed countries. Proteasome is a key player in multiple myeloma and proteasome inhibitors are the current first-line of treatment. However, these are associated with limited clinical efficacy due to acquired resistance. One of the solutions to overcome this problem is a polypharmacology approach, namely combination therapy and multitargeting drugs. Several polypharmacology avenues are currently being explored. The simultaneous inhibition of EZH2 and Proteasome 20S remains to be investigated, despite the encouraging evidence of therapeutic synergy between the two. Therefore, we sought to bridge this gap by proposing a holistic in silico strategy to find new dual-target inhibitors. First, we assessed the characteristics of both pockets and compared the chemical space of EZH2 and Proteasome 20S inhibitors, to establish the feasibility of dual targeting. This was followed by molecular docking calculations performed on EZH2 and Proteasome 20S inhibitors from ChEMBL 25, from which we derived a predictive model to propose new EZH2 inhibitors among Proteasome 20S compounds, and vice versa, which yielded two dual-inhibitor hits. Complementarily, we built a machine learning QSAR model for each target but realised their application to our data is very limited as each dataset occupies a different region of chemical space. We finally proceeded with molecular dynamics simulations of the two docking hits against the two targets. Overall, we concluded that one of the hit compounds is particularly promising as a dual-inhibitor candidate exhibiting extensive hydrogen bonding with both targets. Furthermore, this work serves as a framework for how to rationally approach a dual-targeting drug discovery project, from the selection of the targets to the prediction of new hit compounds.<\/jats:p>","DOI":"10.3390\/molecules26185574","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T21:47:21Z","timestamp":1631656041000},"page":"5574","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma"],"prefix":"10.3390","volume":"26","author":[{"given":"Filipe G. A.","family":"Estrada","sequence":"first","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"},{"name":"Department of Pharmaceutical Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"},{"name":"Institute of Chemistry, University of Tartu, Ravila 14a, 50411 Tartu, Estonia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8570-2903","authenticated-orcid":false,"given":"Silvia","family":"Miccoli","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"},{"name":"Department of Drug Science and Technology, University of Turin, Via Verdi 8, 10124 Torino, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7039-0022","authenticated-orcid":false,"given":"Nat\u00e1lia","family":"Aniceto","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"},{"name":"Department of Pharmaceutical Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-4446","authenticated-orcid":false,"given":"Alfonso T.","family":"Garc\u00eda-Sosa","sequence":"additional","affiliation":[{"name":"Institute of Chemistry, University of Tartu, Ravila 14a, 50411 Tartu, Estonia"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-9181","authenticated-orcid":false,"given":"Rita C.","family":"Guedes","sequence":"additional","affiliation":[{"name":"Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"},{"name":"Department of Pharmaceutical Sciences and Medicines, Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/JOP.19.00244","article-title":"Current treatment strategies for multiple myeloma","volume":"16","author":"Branagan","year":"2020","journal-title":"J. Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","article-title":"Dual or multi-targeting inhibitors: The next generation anticancer agents","volume":"143","author":"Raghavendra","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/17460441.2013.743991","article-title":"Multitarget ligands in antibacterial research: Progress and opportunities","volume":"8","author":"East","year":"2012","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/med.21600","article-title":"Epigenetic polypharmacology: A new frontier for epi-drug discovery","volume":"40","author":"Tomaselli","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fchem.2019.00071","article-title":"Editorial: Multi-target-directed ligands (MTDL) as challenging research tools in drug discovery: From design to pharmacological evaluation","volume":"7","author":"Alcaro","year":"2019","journal-title":"Front. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Guedes, R.A., Aniceto, N., Andrade, M.A.P., Salvador, J.A.R., and Guedes, R.C. (2019). Chemical patterns of proteasome inhibitors: Lessons learned from two decades of drug design. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215326"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/onc.2012.477","article-title":"Chromatin H3K27me3\/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells","volume":"32","author":"Curry","year":"2013","journal-title":"Oncogene"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","article-title":"A polycomb repression signature in metastatic prostate cancer predicts cancer outcome","volume":"67","author":"Yu","year":"2007","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9211","DOI":"10.1158\/0008-5472.CAN-09-1622","article-title":"EZH2 is essential for glioblastoma cancer stem cell maintenance","volume":"69","author":"Riggi","year":"2009","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00401-012-1070-9","article-title":"Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma","volume":"125","author":"Dubuc","year":"2013","journal-title":"Acta Neuropathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","article-title":"Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition","volume":"23","author":"Rizq","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ashtiani, M., Salehzadeh-Yazdi, A., Razaghi-Moghadam, Z., Hennig, H., Wolkenhauer, O., Mirzaie, M., and Jafari, M. (2018). A systematic survey of centrality measures for protein-protein interaction networks. BMC Syst. Biol., 12.","DOI":"10.1186\/s12918-018-0598-2"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology\u2014Foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Albertini, C., Naldi, M., Petralla, S., Strocchi, S., Grifoni, D., Monti, B., Bartolini, M., and Bolognesi, M. (2021). From combinations to single-molecule polypharmacology\u2014cromolyn-ibuprofen conjugates for alzheimer\u2019s disease. Molecules, 26.","DOI":"10.3390\/molecules26041112"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/17460441.2018.1413089","article-title":"Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery","volume":"13","author":"Ravikumar","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"10299","DOI":"10.1021\/acs.jmedchem.8b01487","article-title":"Discovery of the first-in-class dual histone deacetylase-proteasome inhibitor","volume":"61","author":"Bhatia","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/acs.jmedchem.9b02161","article-title":"Discovery of peptide boronate derivatives as histone deacetylase and proteasome dual inhibitors for overcoming bortezomib resistance of multiple myeloma","volume":"63","author":"Zhou","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1016\/j.bmc.2017.01.020","article-title":"A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids","volume":"25","author":"Zhu","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9092","DOI":"10.1038\/s41598-018-27175-w","article-title":"An evolutionarily conserved structural platform for PRC2 inhibition by a class of Ezh2 inhibitors","volume":"8","author":"Bratkowski","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader","year":"2016","journal-title":"Science"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"Lyu","year":"2019","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1039\/C9NJ04713A","article-title":"Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents","volume":"44","author":"Zhou","year":"2020","journal-title":"N. J. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/15384101.2020.1729450","article-title":"A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells","volume":"19","author":"Huang","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7617","DOI":"10.1021\/acs.jmedchem.6b00855","article-title":"Structure-activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors","volume":"59","author":"Yang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"34984","DOI":"10.1038\/srep34984","article-title":"Structural insights into conformational stability of both wild-type and mutant EZH2 receptor","volume":"6","author":"Aier","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1248\/cpb.c19-00550","article-title":"Identification and assessments of novel and potent small-molecule inhibitors of EED\u2013EZH2 interaction of polycomb repressive complex 2 by computational methods and biological evaluations","volume":"68","author":"Zhu","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Aier, I., and Raj, U. (2016, January 4\u20136). Exploring the role of EZH2 (PRC2) as epigenetic target. Proceedings of the 2016 International Conference on Bioinformatics and Systems Biology (BSB), Allahabad, India.","DOI":"10.1109\/BSB.2016.7552131"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1570164613666161124095758","article-title":"Identification of Novel Inhibitors for Disrupting EZH2-EED Interactions Involved in Cancer Epigenetics: An In-Silico Approach","volume":"13","author":"Raj","year":"2016","journal-title":"Curr. Proteom."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1007\/s00894-014-2515-y","article-title":"Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations","volume":"20","author":"Li","year":"2014","journal-title":"J. Mol. Model."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ejmech.2016.05.049","article-title":"Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening","volume":"121","author":"Ettari","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1080\/07391102.2019.1666743","article-title":"Quantitative structure-activity relationship and molecular docking studies on human proteasome inhibitors for anticancer activity targeting NF-\u03baB signaling pathway","volume":"38","author":"Yadav","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.4161\/cc.8.12.8798","article-title":"Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells","volume":"8","author":"Kazi","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.compbiolchem.2018.08.009","article-title":"Pharmacophore-based virtual screening for identifying \u03b25 subunit inhibitor of 20S proteasome","volume":"77","author":"Arba","year":"2018","journal-title":"Comput. Biol. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112890","DOI":"10.1016\/j.ejmech.2020.112890","article-title":"Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide\/carboxamide derivatives as proteasome inhibitors","volume":"209","author":"Uysal","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"W530","DOI":"10.1093\/nar\/gkab294","article-title":"PLIP 2021: Expanding the scope of the protein-ligand interaction profiler to DNA and RNA","volume":"49","author":"Adasme","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2174\/138620711797537058","article-title":"Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking","volume":"14","author":"Subramaniam","year":"2011","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1021\/acs.jcim.1c00045","article-title":"Epigenetic target profiler: A web server to predict epigenetic targets of small molecules","volume":"61","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0166-1280(99)00360-7","article-title":"Molecular fields in quantitative structure-permeation relationships: The VolSurf approach","volume":"503","author":"Cruciani","year":"2000","journal-title":"J. Mol. Struct. THEOCHEM"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3109\/14756366.2011.605359","article-title":"Structural analysis of structurally diverse \u03b1-glucosidase inhibitors for active site feature analysis","volume":"27","author":"Moorthy","year":"2012","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.compbiolchem.2018.03.002","article-title":"Molecular modeling on porphyrin derivatives as \u03b25 subunit inhibitor of 20S proteasome","volume":"74","author":"Arba","year":"2018","journal-title":"Comput. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00894-009-0515-0","article-title":"Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: Docking and molecular dynamics study","volume":"15","author":"Zhang","year":"2009","journal-title":"J. Mol. Model."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkw1074","article-title":"The ChEMBL database in 2017","volume":"45","author":"Gaulton","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: An open chemical toolbox","volume":"3","author":"Banck","year":"2011","journal-title":"J. Cheminform."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/acs.jctc.8b01026","article-title":"OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules","volume":"15","author":"Roos","year":"2019","journal-title":"J. Chem. Theory Comput."},{"key":"ref_57","unstructured":"(2021, July 23). RDKit: Open-Source Cheminformatics. Available online: http:\/\/www.rdkit.org."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1021\/jm9602928","article-title":"The properties of known drugs. 1. Molecular frameworks","volume":"39","author":"Bemis","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/bioinformatics\/btr055","article-title":"fconv: Format conversion, manipulation and feature computation of molecular data","volume":"27","author":"Neudert","year":"2011","journal-title":"Bioinformatics"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: Fast, flexible, and free","volume":"26","author":"Lindahl","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s008940100045","article-title":"GROMACS 3.0: A package for molecular simulation and trajectory analysis","volume":"7","author":"Lindahl","year":"2001","journal-title":"J. Mol. Model."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theory Comput."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/ct100747y","article-title":"Validation of the GROMOS 54A7 force field with respect to \u03b2-peptide folding","volume":"7","author":"Huang","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6269","DOI":"10.1021\/j100308a038","article-title":"The missing term in effective pair potentials","volume":"91","author":"Berendsen","year":"1987","journal-title":"J. Phys. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1063\/1.448118","article-title":"Molecular dynamics with coupling to an external bath","volume":"81","author":"Berendsen","year":"1984","journal-title":"J. Chem. Phys."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"014101","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"Bussi","year":"2007","journal-title":"J. Chem. Phys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: A new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/18\/5574\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:02:38Z","timestamp":1760166158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/18\/5574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,14]]},"references-count":67,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["molecules26185574"],"URL":"https:\/\/doi.org\/10.3390\/molecules26185574","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,14]]}}}